The platelet and megakaryocyte cytoskeletons are essential for formation and function of these cells. A dynamic, properly organised tubulin and actin cytoskeleton is critical for the development of the megakaryocyte and the extension of proplatelets. Tubulin in particular plays a pivotal role in the extension of these proplatelets and the release of platelets from them. Tubulin is further required for the maintenance of platelet size, and actin is the driving force for shape change, spreading and platelet contraction during platelet activation. Whilst several key proteins which regulate these cytoskeletons have been described in detail, the formin family of proteins has received less attention. Formins are intriguing as, although they were initially believed to simply be a nucleator of actin polymerisation, increasing evidence shows they are important regulators of the crosstalk between the actin and microtubule cytoskeletons. In this review, we will introduce the formin proteins and consider the recent evidence that they play an important role in platelets and megakaryocytes in mediating both the actin and tubulin cytoskeletons. 
Formins

Actin filament nucleation and elongation
Formin proteins were first identified in mice from studies on abnormal limb development (1,2) with homologues subsequently being found in drosophila and yeast (3) . A list of the formin proteins expressed in mammalian cells is given in Table I . Formins have the ability to both nucleate and accelerate the elongation of linear actin filaments. They play a crucial role in the assembly of cytoskeletal structures such as filopodia, lamellipodia and stress fibres and are therefore required for a range of cellular processes including cell adhesion, cell division and cell motility (4) . These multidomain proteins are defined by the presence of highly conserved Formin Homology 1 (FH1) and Formin Homology 2 (FH2) domains and a less well-conserved FH3 domain (Figure 1(a) ). Formins function as a homodimer with dimerisation mediated via the dimerisation domain (DD), a component of the FH3 domain (5) and the FH2 domains (Figure 1(b) ). The FH2 domains form a doughnut-shaped head-to-tail dimer which nucleates actin filaments. Indeed, it has been shown that the FH2 domains alone are sufficient for actin filament nucleation probably via the stabilisation of spontaneously formed actin dimers (6) . The FH2 domain remains processively attached to actin filament barbed ends facilitating addition of actin monomers to support elongation and shielding the filament from abundant capping proteins (7) (8) (9) . The FH1 domains recruit profilin bound G-actin molecules, bringing them into close proximity with the barbed end and thus accelerating filament elongation (10) (Figure 1(c) ).
Activation of formin proteins
Formin proteins exist in an auto-inhibited state. Diaphanousrelated formins (DRFs) contain conserved regulatory domains; a C-terminal Diaphanous Auto-regulatory Domain (DAD) and an N-terminal Diaphanous Inhibitory Domain (DID -which forms part of the FH3 domain) (11) . Intramolecular interactions between the DAD and DID lead to auto-inhibition of formin activity (Figure 1(d) ). As a general rule, this auto-inhibition can be relieved upon the interaction of the GTPase-binding domain (GBD) with an active Rho GTPase (12) . Therefore, Rho GTPases recruit formins to different locations within the cell for localised actin filament assembly. DIAP1 (also known as DIAPH1, but commonly known as mDia1) is the most studied formin and was found as an effector of the small GTPase RhoA in the formation of actin stress fibres (13) . In its active form, it is a potent actin nucleator and accelerates filament elongation. mDia1 is activated as described above by GTP bound Rho GTPase binding to the GBD causing displacement of the DAD domain from the N terminal region of mDia1. However, other members of the formin protein family show different mechanisms of DAD release; for example, DAAM1 is activated when the PDZ domain of the Dishevelled (Dvl) protein binds to the DAD domain rather than by Rho binding (14) .
Similarly, although FHOD1 is recruited to the plasma membrane by active Rac1 binding, this formin seems not to be activated by GTPase interactions. Instead the auto-inhibitory state is disturbed by the phosphorylation of residues in its DAD domain by Rho effector kinase ROCK (15) and cGMP-dependent protein kinase 1 (PRKG1) (16) .
Differences also exist in the activity and functions of individual formins in cells. In comparison with mDia1, FHOD1 is less effective at processively elongating actin filaments, but rather acts as an actin bundling factor while protecting filaments from depolymerisation (17, 18) . INF2 has a Wiskott-Aldrich syndrome homology region 2 (WH2) domain which replaces the DAD Copies per mouse platelet 4 Human platelet transcript abundance 5, 6 Mouse platelet transcript abundance 5, 6 Dishevelled-associated activator of morphogenesis 1 Figure adapted from (11, 68) .
found in the DRFs and is able to bind monomeric actin. Interestingly, INF2 is able to sever filaments and accelerate actin filament depolymerisation on the pointed end by virtue of its WH2 domain, as well as to nucleate and elongate actin via its FH2 domain. The switch between polymerisation and depolymerisation activity is thought to be mediated by the hydrolysis of bound ATP within actin subunits upon addition to a filament and the subsequent release of phosphate (19, 20) .
Microtubule organisation and dynamics
In addition to actin filament assembly, formins regulate microtubule organisation and dynamics, providing a means of crosstalk between the two cytoskeletons. Initial evidence for this came from studies whereby activation of endogenous mDia1 by overexpression of a DAD domain led to a stabilisation of microtubules (21) . mDia1 has been shown to interact with microtubules through its FH2 domain. This interaction is via both direct binding to microtubules and through the microtubule plus end tracking proteins EB1, APC 100 and CLIP170 (22) . Henty-Ridilla et al. found that CLIP170 increased the elongation rate of actin filaments assembled by formins including DAAM1 and INF2 and that a complex of mDia1/CLIP170 and EB1 triggered accelerated actin polymerisation from microtubule plus ends (23) . The strength and effects of interactions between FH2 domains and microtubules vary depending upon the source of the FH2 domain. For example, the FH2 domain from mDia2 binds with a 1:1 stoichiometry to tubulin whereas that from INF2 and mDia1 binds with a 1:3 stoichiometry (24). In addition, binding of microtubules to mDia2 FH2 domains strongly inhibits actin polymerisation where binding has no effect of INF2 FH2 domains (24) . Furthermore, DAAM1 can bind to both actin and microtubules simultaneously linking actin polymerisation to regions of stable microtubules (25) and co-alignment of actin filaments and microtubules is observed when active fragments of mDia1 and FHOD1 are expressed (26, 27) . Microtubule stability can also be regulated by post-translational modification of alpha tubulin via acetylation and detyrosination (28, 29) , and it has been demonstrated that FH1-FH2 domains from the majority of formin proteins can induce the formation of stabilised microtubules through these post-translational modifications (30, 31) . Finally, although it has been shown that regulation of microtubule stability by formins can be independent of their actin polymerisation activity (30) , it is likely that in vivo these functions are closely coordinated. Indeed, more recently, it has been suggested that different formins could work in series or in collaboration to regulate microtubule stability or actin assembly as evidenced for mDia1 and INF2 (32) . The proposed role of formins in actin and microtubule organisation is summarised in Figure 2 .
Expression of formins in megakaryocytes and platelets
In mammals, the family of formin proteins contains 15 members which are subdivided into eight groups based on their protein domain architecture. The formins vary in their localisation, binding partners and regulation, and show differences in the strength and efficiency of their actin nucleation and elongation activity (11) indicating that they may play many specialised roles in different cell types. Of these 15 formins only a subset are expressed in platelets and megakaryocytes.
Thomas et al. had previously reported on formin expression in platelet and megakaryocytes using SAGE and Haematlas databases (33) . Since this time, further studies and advances in technology have allowed for more accurate measurements of the formins at both the gene and protein expression level in platelets and megakaryocytes (34) (35) (36) (37) (38) . In these genomic and proteomic studies, the expression profile of the mammalian formin proteins changes over the developmental time course of the megakaryocyte. In humans, expression of all formin proteins is low in CD34 + progenitor cells. Over the course of progenitor cell commitment to the megakaryocyte lineage and differentiation into mature cells, the formins DAAM1, DIAPH1 (mDia1) and FHOD1 all significantly increase their expression (Figure 3(a) ). A similar pattern is observed in mouse cells with a few differences (Figure 3(b) ), i). Fmnl3 appears highly expressed in the LT-and ST-HSC and its expression decreases during differentiation -in mature megakaryocytes, there is still some expression of this formin, ii) there appears to be a small increase in expression of Fhdc1 in maturing mouse megakaryocytes and iii) Inf2 increases in its expression during differentiation.
In platelets, studies have used mass spectrometry-based proteomics and RNA transcript abundance to assess the levels of the formin proteins in human and mouse platelets (Table I) . In human platelets, DAAM1, mDia1 and FHOD1 are all found at the protein level, matching closely the gene expression data from megakaryocytes. However, interestingly, INF2 is also found in human platelets despite no expression being reported in megakaryocytes and there is no evidence for mDia2 expression in human platelets even though it has been shown previously by immunoprecipitation and Western blot (33) . This protein expression pattern is also reflected in the RNA transcript abundance in the platelets, with the addition of RNA transcripts for Fmnl1 being observed, despite no evidence for expression at the gene of proteins level in studies in developing megakaryocytes and platelets.
In mouse platelets, again DAAM1, mDia1 and FHOD1 are all found to be expressed along with INF2, which in this case matches the megakaryocyte expression data. This pattern is repeated for the platelet RNA transcript levels. A very small amount of Fmnl3 protein and transcript is reported and this is likely to be a carry over as this formin is expressed early in differentiation. Taken all together, data from the genomics, proteomics and other studies indicate that DAAM1, mDia1 and FHOD1 are the major formin proteins in platelets, with a previously unidentified expression of INF2, particularly in mouse platelets. The presence of mDia2 in human platelets is unclear.
Roles of formin proteins in megakaryocytes and platelets
The formins mDia1 and DAAM1 were first identified in human platelets by RhoA affinity chromatography with the affinity for active RhoA (RhoA-GTP) being approximately 100× (mDia1) and 200× (DAAM1) higher than for inactive RhoA (RhoA-GDP). Both formins were shown to associate with RhoA in platelets activated with thrombin and were both able to initiate actin polymerisation in platelet lysates (39). Subsequently, it was shown that mDia1 moved to the cytoskeleton (Triton insoluble fraction) in activated platelets in a PI3-kinase dependent manner (40 
mDia1 function in platelets and megakaryocytes
Formin protein function has been investigated using knockout mouse models, primarily for mDia1. Two independent labs have created Diaph1 (mDia1) null mice (42, 43) . Both models are apparently healthy and breed normally but display consistent defects in white blood cells including lymphopenia, myeloproliferative syndrome, myelodysplastic syndrome and reduced adhesion, migration and chemotaxis of neutrophils and lymphocytes (42) (43) (44) (45) (46) (47) . Studies on the platelets of the mDia1 knockout mice revealed no major phenotype in terms of activation, aggregation or spreading (33) . We have tested platelet function following the global inhibition of formin FH2 domains using the small molecule inhibitor SMIFH2 and found that it blocks platelet spreading and cytoskeletal organisation, indicating that formin activity is required for platelet spreading (Thomas, Unpublished data). The reason for the lack of phenotype in mDia1 KO platelets is unclear, but is presumably due to functional redundancy with other formin proteins; in the milieu of the activated platelet, it is highly likely that the abundance of free actin barbed ends, profilin bound G-actin and activated Rho family small GTPases allows for formin mediated actin assembly, even in the absence of one of the formin family members. Alternatively, the lack of phenotype in mDia1 KO platelets could be because mDia1 plays a very specific minor role in the platelet or may primarily play a role in megakaryocytes which effects are carried over in platelets. These functions may not manifest themselves during platelet activation, but affect the resting platelet. Examples of these specific roles include the organisation of actin filaments relative to microtubules in the resting platelet or in regulating the balance of tubulin post-translational modifications that influence microtubule Figure 3 . Expression of mammalian formin proteins during megakaryocyte development.a) Relative expression levels of the 15 mammalian formin proteins during the development of human megakaryocytes. CD34+ cells from umbilical cord blood were cultured in vitro in the presence of thrombopoietin and interleukin 1β and gene expression quantified by RNA-seq. Data are taken from the Blueprint epigenome project (http://www.blueprint-epigenome.eu/) and (35) . * Note -no data was available for the expression of GRID2IP. b) Relative expression levels of the 15 mammalian formin proteins during the development of mouse megakaryocytes. Bone marrow cells from C57BL/6 mice were sorted using FACS and gene expression quantified by microarrays. Data are taken from the haemosphere database (http://haemosphere. org/) and (36) . For both panels, Log2 of normalised gene expression is represented by a heat map where red equals increased gene expression. Gene names in this figure and throughout the review use the conventions of the HUGO Gene Nomenclature Committee (www.genenames.org) and the Mouse Genome Informatics (www.informatics.jax.org) for human and mouse genes, respectively. stability and dynamics. This hypothesis is supported by the observation that in our hands, mDia1 knockout mice have an increased platelet size, but normal platelet count (Thomas, Unpublished data) indicating either a defect in platelet formation or an impairment of the ability of the microtubule coil to maintain normal platelet size. This hypothesis, however, remains to be tested. mDia1 function has also been directly investigated in megakaryocytes. Pan et al. (48) used shRNA in human CD34+ derived megakaryocytes to knockdown mDia1 expression to approximately 50-60% of controls. In these cells, proplatelet formation (PPF) was increased, F-actin polymerisation was decreased and the stability of microtubules was increased, as assessed by increased Glu-tubulin (28, 29) . These data indicate that partial inactivation of mDia1 activity in mature megakaryocytes is required to allow proplatelet formation. This effect is proposed to be mediated through reducing actin-myosin contractile forces in the mature megakaryocyte which allows for the protrusion of proplatelets, an effect also seen in inhibition of myosin IIa (48) . However, this effect may also be related to observed changes in microtubule stability which could alter motor protein interaction with microtubules facilitating proplatelet extension (49) . Intriguingly, platelet counts are normal in the mDia1 knockout mouse (Thomas, Unpublished data) indicating a possible difference between human and mouse cells, or some compensatory mechanism in the knockout. As indicated above, the mDia1 knockout platelets are increased in size (Thomas, Unpublished data) suggesting that there is a defect in proplatelet formation/ release when mDia1 is absent. In addition, the knockdown experiments performed by Pan et al. were done after megakaryocyte differentiation, and so, the effect of reduced mDia1 expression on human megakaryocyte development was not studied.
In addition to the loss of mDia1, Pan et al. also investigated the expression of constitutively active (CA) mDia1 (just the FH1 and FH2 domains) (48) . In these cells, a decrease in PPF formation, an increase in F-actin polymerisation and stress fibre formation was observed (48) which mirrored the results obtained in the mDia1 knockdown cells. More recently, Stritt et al. have identified human patients with a gain of function mutation in the autoregulatory domain of DIAPH1 (R1213*) which leads to a constitutively active protein (50) . Patients with the R1213* variant display macrothrombocytopenia and their platelets have abnormal distributions and size of α-granules, vacuoles and membrane complexes (50) . Similar to that observed by Pan et al., the R1213* variant caused a decrease in PPF in CD34+ derived megakaryocytes providing support to the hypothesis that formin mediated F-actin polymerisation can reduce proplatelet formation due to actin-myosin contractile forces reducing protrusion (as described above). It also indicates that proper regulation of formin activity is required for correct delivery of granules, etc. to the newly forming platelets.
A key difference between the two studies of CA mDia1 is related to their effect on microtubule stability in megakaryocytes and platelets. Pan et al. identified that CA mDia1 gave rise to microtubules with decreased stability, whereas Stritt et al. observed more stable microtubules. Indeed, the finding of Pan seems to go against the general ability of FH1-FH2 domains to increase microtubule stability (30, 31) . This difference may well be due to the differences in the constitutively active mDia1 used; the mDiaΔN3 used by Pan et al. has additional N terminal deletions compared to the R1213* which may be important in determining how formins interact with microtubules. For example, loss of the Rho-GTPase binding domain in mDiaΔN3 CA mDia1 may potentially cause it to be mis-localised and therefore limit its ability to increase microtubule stabilisation. Likewise, R1213* mDia1 may also lose the ability to be correctly localised within the platelet which would affect its interaction with actin and microtubules. Indeed, in patient platelets, R1213* variant mDia1 displayed altered cellular localisation and gave rise to increased F-actin content and disorganised microtubule organisation (50) . Additional families with the R1213* mutation have been identified and a further mutation in the auto-regulatory domain of mDia1 has been reported (A1210Serfs*31), both of which display thrombocytopenia (51) although the actin and microtubule organisation has not been reported in these cases. Finally, although there were clear differences in R1213* platelet cytoskeletons, there was no observed difference in platelet aggregation to a range of agonists (50) . This data, taken in light of the mDia1 knockout mouse phenotype, strongly suggest that mDia1 is redundant in platelet activation and its major role is in the formation of platelets from the megakaryocyte.
Other formin family members in platelets and megakaryocytes
Knockout mice have been generated for other formin proteins (DAAM1, DAAM2, FMN2, mDia2, FHOD3 and INF2) and a range of phenotypes described ranging from cardiac development phenotypes (52) (53) (54) (55) , infertility (56, 57) , impaired red blood cell production (58) (59) (60) and kidney development and function (61, 62) . However, despite this, little is known about the effect of loss of these formin proteins on megakaryocyte and platelet function. It is likely that there is significant functional redundancy between the formins or in megakaryocytes and platelets and so phenotypes may be masked by the presence of other formin proteins. Additionally, there may be genetic compensation for loss of protein function which would supress the effect of a harmful mutation (63) . A systematic knockout of all four formins expressed in megakaryocytes and platelets would help to answer this but would be an expensive and complicated study. As can be seen from the Stritt study (50), a useful avenue of research is through identifying mutations in formin proteins that give rise to thrombocytopenias and/or platelet function disorders via patient genotyping studies. Many mutations will give rise to a protein with an altered function, rather than complete loss of the protein and so may allow more subtle phenotypes to be identified.
Future perspectives
As discussed above, the formins are an important family of actin and microtubule regulatory proteins whose ability to i) nucleate and elongate actin filaments, ii) bundle and organise both actin filaments and microtubules and iii) regulate the stability and interactions of microtubules, places them at the centre of cellular cytoskeletal organisation. In relation to platelet function, global inhibition of formins prevents platelet spreading indicating their importance in platelet actin dynamics, however, as of yet, the precise contribution of each of the expressed formins to platelet actin dynamics has yet to be elucidated. In terms of the megakaryocyte, mDia1 has been shown to be important for proper platelet formation, with changes in platelet size, number or morphology being reported for both loss and over-activation of mDia1. Thus, mDia1 likely mediates platelet both the actin and tubulin cytoskeletons during platelet formation where actin-myosin contractility and stable microtubules for proplatelet extension need to be carefully balanced. The roles of Daam1, Fhod1 and INF2 in platelets and megakaryocytes remain to be determined and will require either knockout mouse models, identification of disease causing mutations or induced pluripotent stem cell line studies to understand their functions.
The different classes expressed in megakaryocytes and platelets suggest that they may be playing different roles in the function of these cells. Furthermore, the upstream signalling proteins that activate formins are different depending on the formin (e.g. mDia1 is activated by RhoA, Fhod1 by ROCK and Rac1 and Daam1 by binding to Dvl). These differences indicate that formins may be involved with different processes or in different subcellular localisations in megakaryocytes and platelets which remain to be uncovered. In addition, the downstream effects of formin activation may be specific. For example, mDia1 has been demonstrated to be required for formation of the mother actin filaments upon which ARP2/3 complex can generate lamellipodial protrusions (64) and studies reviewed here have highlighted their key role in coordinating microtubule dynamics. Thus, this may be a mechanism by which mDia1 specifically coordinates the initiation of proplatelet extensions, whereas other formins may regulate different megakaryocyte developmental pathways, for example, regulating the actin pool during endomitosis. In addition, the demonstration that profilin can regulate platelet microtubule dynamics most likely via its interaction with formin proteins (65) highlights the complex and important role that formins may have in regulating actin and microtubules in megakaryocytes and platelets. It is also known that the 3D environment and particularly matrix stiffness is important for regulating megakaryocytes and platelet function (66) . Recent observations that mDia1:RhoA can act as a major biochemical switch for mechanosensing/mechanotransduction (67) highlights that in the physiological environment formins may be more important for proper function and as such strides should be taken towards studying them within bone marrow megakaryocytes or within platelets in thrombi. Studies such as these will be important as we consider the causes of uncharacterised thrombocytopenias and bleeding diatheses in patients or as we strive to improve the in vitro production of platelets for clinical use, where subtle modifications of proteins that regulate proplatelet formation could increase platelet yields or quality.
